2024-11-18 - Analysis Report
## Eli Lilly and Co. (LLY) Stock Review

**1. Performance Relative to S&P 500 (VOO):**

Eli Lilly and Co. (LLY) is a pharmaceutical company engaged in the research, development, and manufacturing of pharmaceutical products.  Over the period analyzed, LLY's cumulative return (585.94) significantly outperformed the S&P 500's cumulative return (123.86). The difference is 462.08, placing it at the 68.9th percentile of its historical performance range relative to the S&P 500.  This indicates a substantial outperformance. The provided alpha values consistently show positive outperformance compared to the benchmark (S&P500), ranging from 0.5 to 0.8.  The beta values, generally around 0.7, suggest lower volatility than the overall market.

**2. Recent Price Movement:**

* **Closing Price:** 746.2 (Last market: 745.89)
* **5-day Moving Average:** 798.03
* **20-day Moving Average:** 839.19
* **60-day Moving Average:** 891.11

The stock is currently trading below all three moving averages, suggesting a downward trend.

**3. Technical Indicators and Expected Return:**

* **RSI (23.19):**  Indicates the stock is in oversold territory, potentially suggesting a bounce.
* **PPO (-0.73):**  Negative value suggests bearish momentum.
* **20-day Relative Divergence (-22.87):** Shows a recent decrease in relative strength.
* **Expected Return (168.86%):**  Suggests a significant outperformance of the S&P 500 over the long term (2+ years) if the current trend reverses and a long term investment strategy is employed. The closing price of 745.89 is below the moving averages;  no immediate significant price jump or crash is evident from this information alone.

**4. Recent Financial Performance:**

The provided financial data shows fluctuating EPS and revenue.  While the most recent quarter (2024-10-30) shows a lower EPS than previous quarters, further analysis is needed to determine if this is a trend or an anomaly.  There is no information regarding earnings estimates, therefore comparison between actual and expected earnings is not possible.

**6. Financial Statement Analysis:**

* **Revenue and Profitability:**  Consistent high revenue and profit margins, indicating strong financial health and operational efficiency.  The profitability (represented by profit margin) is high and stable.
* **Capital and Profitability:** Shows fluctuation in ROE, possibly due to various factors including seasonality or short-term investment strategies. Further investigation is required to understand the underlying causes.

**7. News and Recent Issues:**

*(This section requires access to real-time news sources like Shacknews and Finbold.  I cannot provide specific news items without access to current data.  Please provide links to relevant articles for a comprehensive analysis.)*  A review of recent earnings calls (if available) is also needed to understand the market outlook and analyst opinions on future performance.

**8. Summary:**

LLY has significantly outperformed the S&P 500 over the historical period analyzed, showing consistent positive alpha. However, recent price action suggests a short-term bearish trend, indicated by the price being below moving averages, a negative PPO, and an oversold RSI. Despite the relatively low current price, long-term projections suggest considerable potential for outperformance.  The fundamental picture shows strong revenue and profit margins, but further analysis of the EPS fluctuation, ROE variation, and recent news (especially earnings calls and analyst opinions) is crucial for a comprehensive assessment of the investment potential.   The lack of explicit earnings estimates prevents a solid conclusion about the most recent reported quarterly results.

**9. Conclusion:**

This analysis shows that Eli Lilly and Co (LLY) is a well-performing company with a history of high revenue and profitability. However, the current price action shows a downward trend which needs further investigation.  The long-term outlook remains strong, with expected high returns compared to the market. A thorough review of recent news, earnings calls, and a detailed analysis of the recent EPS and ROE fluctuations are recommended before making any investment decisions.  The oversold RSI suggests a potential short-term bounce, but the underlying bearish momentum requires caution. A long-term investment strategy could be considered, but short-term trading should be approached cautiously given the current indicators.
